Syringe for inducing therapeutically-effective proteins
AssigneeOrthogen Gentechnologie GmbH
InventorsJulio Reinecke, Hans Meijer, Peter Wehling
Life of this patent
Estimating the term…
Abstract
A syringe for inducing therapeutically-effective proteins includes a syringe and an inner structure having an inductor disposed thereon for encouraging development of a desired protein.
Claims27
A syringe with an inner structure consisting of at least one of the group consisting of materials containing polystyrene and materials containing glass, the inner structure being coated with an inductor, wherein the inner structure is coated with the inductor independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the inductor is immunoglobulin G.
A syringe with an inner structure consisting of at least one of the group consisting of materials containing polystyrene and materials containing glass, the inner structure being coated with an inductor, wherein the inner structure is coated with the inductor independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- wherein the syringe further comprises a therapeutically-effective protein disposed in the syringe independent of the introduction of a body fluid into the syringe;
- and
- wherein the therapeutically-effective protein is selected from the group consisting of interleukin 1 receptor antagonist (IRAP), interleukin 4, interleukin 10 and soluble tumour necrosis factor receptor Type I or Type II.
A syringe with an inner structure consisting of at least one of the group consisting of materials containing polystyrene and materials containing glass, the inner structure being coated with an inductor, wherein the inner structure is coated with the inductor independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the inductor comprises immunoglobulin, and wherein the therapeutically-effective protein is selected from the group consisting of interleukin 1 receptor antagonist (IRAP), interleukin 4, interleukin 10 and soluble tumour necrosis factor receptor Type I or Type II.
A syringe comprising:
- an inductor;
- and
- an inner structure comprising at least one of the group consisting of spheres, gels, glass wool, granulated material and particles disposed in the syringe, with the inductor being disposed on said inner structure, wherein the inductor is disposed on said inner structure independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the inductor is immunoglobulin IgG.
A syringe comprising:
- an inductor;
- and
- an inner structure comprising at least one of the group consisting of spheres, gels, glass wool, granulated material and particles disposed in the syringe, with the inductor being disposed on said inner structure, wherein the inductor is disposed on said inner structure independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the therapeutically effective protein is selected from the group consisting of interleukin and soluble tumor necrosis factor.
A syringe comprising:
- an inner structure configured to contact a fluid which is disposed in the syringe;
- and
- an inductor, the inductor disposed as a coating on the inner structure, the inductor being present on the inner structure independent of the introduction of a body fluid into the syringe;
- wherein the inductor is configured to induce production of a therapeutically effective protein in a body fluid once the body fluid is introduced into the syringe, and wherein the protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the protein is a type I or type II tumor necrosis factor receptor.
A syringe comprising:
- an inner structure configured to contact a fluid which is disposed in the syringe;
- and
- an inductor, the inductor disposed as a coating on the inner structure, the inductor being present on the inner structure independent of the introduction of a body fluid into the syringe;
- wherein the inductor is configured to induce production of a therapeutically effective protein in a body fluid once the body fluid is introduced into the syringe, and wherein the protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the therapeutically effective protein is an interleukin.
A syringe comprising:
- an inner structure configured to contact a fluid which is disposed in the syringe;
- and
- an inductor, the inductor disposed as a coating on the inner structure, the inductor being present on the inner structure independent of the introduction of a body fluid into the syringe;
- wherein the inductor is configured to induce production of a therapeutically effective protein in a body fluid once the body fluid is introduced into the syringe, and wherein the protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the therapeutically effective protein is interleukin 1 receptor antagonist.
A syringe with an inner structure consisting of at least one of the group consisting of materials containing polystyrene and materials containing glass, the inner structure being coated with an inductor, wherein the inner structure is coated with the inductor independent of introduction of a body fluid into the syringe;
- wherein the inductor is selected to induce formation of a therapeutically effective protein within a body fluid once the body fluid is introduced into the syringe, and wherein the therapeutically effective protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the therapeutically-effective protein is selected from the group consisting of interleukin 1 receptor antagonist (IRAP), interleukin 4, interleukin 10 and soluble tumour necrosis factor receptor Type I or Type II.
A syringe comprising:
- an inner structure configured to contact a fluid which is disposed in the syringe;
- and
- an inductor, the inductor disposed as a coating on the inner structure, the inductor being present on the inner structure independent of the introduction of a body fluid into the syringe;
- wherein the inductor is configured to induce production of a therapeutically effective protein in a body fluid once the body fluid is introduced into the syringe, and wherein the protein is therapeutically effective for treatment when the protein is introduced into a body;
- and
- wherein the inductor is immunoglobulin.
Dependencies are inferred from the claim text.